A Novel Image-Guided, Automatic, High-Intensity Neurostimulation Device for the Treatment of Nonspecific Low Back Pain by Gorenberg, Miguel et al.
Hindawi Publishing Corporation
Pain Research and Treatment
Volume 2011, Article ID 152307, 6 pages
doi:10.1155/2011/152307
Research Article
A Novel Image-Guided,Automatic,High-Intensity
NeurostimulationDevicefortheTreatmentofNonspeciﬁc
LowBackPain
Miguel Gorenberg,1,2 EladSchiff,2,3 Kobi Schwartz,4 and ElonEizenberg2,5
1Department of Nuclear Medicine, Bnai Zion Medical Center, Haifa, Israel
2The Rappaport Faculty of Medicine, Technion—Israel Institute of Technology, Haifa 32000, Israel
3Department of Internal Medicine, Bnai Zion Medical Center, Haifa, Israel
4Department of Physical Therapy, Bnai Zion Medical Center, Haifa, Israel
5Pain Relief Unit, Rambam Medical Center, Haifa 31096, Israel
Correspondence should be addressed to Miguel Gorenberg, miguel.gorenberg@b-zion.org.il
Received 10 January 2011; Accepted 9 March 2011
Academic Editor: Seiji Ohtori
Copyright © 2011 Miguel Gorenberg et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Purpose. The current pilot study investigates the eﬀectiveness of a novel device in the managementof chronic lowback pain (LBP).
This device is able to automatically measure skin impedance in a selected body area and, immediately afterwards, to stimulate
multiple points that are targeted according to diﬀerentiation in their electrical properties (peripheral nerve ends—milinated A
δ ﬁbers) with high-intensity electrical stimulation. Materials and Methods. Nineteen outpatients were included in the study, 15
females(79%)and4men (21%),meanage52.1±10.8years,alldiagnosedwithnonspeciﬁcchronicLBP.The protocolconsistedof
6 treatment sessions,2–4 days apart. Each sessionincluded a <1 minute automatic impedance screening, followed by a 20-minute
treatment of lowest impedance points according to proprietary algorithms. Outcome Measures. The primary outcome measure
consisted of changes in pain intensity as measured on a 100mm pain visual analogue scale (VAS) obtained at enrollment, before
and 2 hours after each treatment. Secondary outcome measures were the Oswestry Disability Index (ODI) and lumbar ﬂexion
range of motion (ROM) obtained at baseline and each week during treatment. Results.T h em e a n± SD baseline VAS score for all
participantswas61±14.There werenosigniﬁcantchangesinVASscoresbetween enrollmentandbefore theﬁrsttreatment (55±16;
P = .102).During treatment, VAS scores decreased signiﬁcantlycompared with baselinescores by 39±17mm(P<. 001).Notably,
VAS scores of all the patients, except for one, decreased by more than 20mm after the fourth treatment, thus showing marked
improvement in 95% of enrolled patients. ODI decreased throughout the entire treatment period, with signiﬁcant changes from
baselinealready attheﬁrstweek (P = .001).Lumbarﬂexion ROMshowedameanincreaseof2.1cm duringtreatment,butwasnot
statisticallysigniﬁcant.Conclusion.Theresultsofthecurrentpilotstudyshowthattreatmentwiththisnoveldeviceproduced aclin-
ically signiﬁcant reduction in back pain in 95% of patients after four treatment sessions. The decrease both in pain and perceived
disability,combinedwiththeimprovementinROM,supportfurtherinvestigationoftheuseofthistherapyinthetreatmentofLBP.
1.Introduction
Despite the fact that low back pain (LBP) is one of the
most common medical problems in our society [1], current
analgesic therapies remain largely unsatisfactory. Conserva-
tive treatment with anti-inﬂammatory drugs and exercise is
eﬀective for many patients with acute LBP [2]. However,
when the pain symptoms persist, they can interfere with
both physical activity and sleep patterns. While analgesic
medications can provide temporary pain relief, these drugs
may not improve physical function and are associated
with well-known adverse eﬀects [3]. These concerns have
increased interest in nonpharmacological therapies for LBP,
such as transcutaneous electrical nerve stimulation (TENS)
[4], electroacupuncture [5], and percutaneous electrical
nerve stimulation (PENS) [6–8]. Unfortunately, these alter-
natives fall short with respect to duration and magnitude of
analgesia.2 Pain Research and Treatment
Localized manual high-intensity neurostimulation de-
vicesareappliedtosmallsurface areastostimulateperipheral
nerve endings (A δ ﬁbers), thus causing the release of endo-
genous endorphins [9, 10]. This procedure, often described
as “hyperstimulation analgesia”, has been investigated in
several controlled studies, showing a positive response in
87% of patients [9]. However, such treatments are time con-
suming and cumbersome, and require previous knowledge
of the localization of peripheral nerve endings responsible
for LBP or manual impedance mapping of the back. These
limitations prevent their extensive utilization [9, 11].
The purpose of the present pilot study was to assess
the eﬀectiveness of a novel device capable of automatically
measuring skin impedance in a selected body area and,
immediately afterwards, of stimulating multiple points that
are targeted according to diﬀerentiation in their electrical
propertiesand proprietaryimage processing algorithms with
high intensity yet nonpainful electrical stimulation (Nervo-
Stim, Nervomatrix Ltd., Netanya, Israel).
2.Methods
2.1. Selection of Participants. This pilot study was conducted
at the Bnai Zion Medical Center, Department of Physio-
therapy from August 2009 to February 2010. Subjects with
chronic nonspeciﬁc LBP were recruited through the hospi-
tal’s e-mail system, and most of the participants belonged to
the staﬀ working at the hospital. Participants were screened
using an LBP examination form and participant history
sheet. Their recruitment to the study was based on strict
inclusion and exclusion criteria (Table 1). Nonspeciﬁc LBP
was deﬁned as pain below the twelfth costal margin and
above the inferior gluteal folds, not attributed to recog-
nizable, known, speciﬁc pathology (e.g., infection, tumour,
osteoporosis, ankylosing spondylitis, fracture, inﬂammatory
process, radicular syndrome, or cauda equine syndrome).
Screening of all participants was carried out by a qualiﬁed
physiotherapist who determined, by subjective and objective
examination, whether the participants had nonspeciﬁc LBP.
Ethics committee approval was obtained for this study, and
all participants gave informed consent. NIH clinical trial
01132300.
3.StudyDesign
Allsubjectsfollowed the treatment protocol,which consisted
of 6 sessions, twice-weekly, for 3 weeks (Figure 1). Each
session included an automatic screening (<1m i n u t e )a n d
treatment for 20 minutes with the Nervo-Stim device.
Participants completed VAS measurements at enroll-
ment, before and 2 hours after each treatment. Measure-
ments for range of motion (ROM) of the lower back and
completion of the Oswestry Disability Index (ODI) were
obtained at enrollment and each week during the study. The
examiners, licensed physical therapists(HV, NB),applied the
devicesandobtainedallVAS,ODI,andROMmeasurements.
Subjects were advised to avoid new treatments during the
time of the study and were instructed not to alter their usual
pattern of medication use.
Recruitment Baseline
Weekly assessment:
Oswestry
ROM
Session assessment:
VAS before session
VAS 2hours after session
Treatment session
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Figure 1: Treatment protocol, which consisted of 6 sessions,twice-
weekly, for 3 weeks. Participants completed VAS measurements at
enrollment, before and2 hours after each treatment. Measurements
ROM of the lower back and completion of ODI were obtained at
enrollment and each week during the study.
After enrollment, the subjects underwent a 1-week pre-
observation period, after which treatment was initiated. The
sessions were conducted between 9AM and 3PM. Ten of the
identiﬁed points by the Nervo-Stim within the screened area
of LBP were automatically selected for treatment according
to proprietary algorithms based on their lowest impedance
measurements. Electrical stimulation was performed on
these 10 selected points for 20 minutes (each point for 2
minutes, in a consecutive order).
The electrical current was DC, and the duty cycle was
continuous. Lowest impedance points were stimulated at
4/30Hz. The intensity of the electrical stimulation was
adjustedtoproducethemostintenseyetnotpainfultolerable
electrical sensation.
3.1. Sample Size. This study was considered a preliminary
study in preparation for a main randomized control trial
(RCT); therefore, a sample of 20 participants was considered
appropriate.
3.2. Technology Description. A device, designed to automat-
ically locate peripheral nerve endings relevant for LBP and
to deliver high-intensity electrical pulses to these areas, has
been developed. Using an array of miniature probes, this
automated, computer-controlled device is capable of instant
impedance scanning of the entire lower back (max scanned
area size 20 ×30cm2)i nles sth a n1m i n ut e.I ta n a ly z esth e2-
dimensional databasedonthemeasured electricalproperties
of each ﬁnite pixel within the scanned region by using
image processing software and algorithms and delivers high-
intensity electrical pulses at selected locations. The squarePain Research and Treatment 3
Table 1: Eligibility criteria.
Inclusion criteria Exclusion criteria
(i) Age 18 years to 70 years (i) Sciatica
(ii) Nonspeciﬁc low back pain that persisted at least 1
month and no longer than 12 months before the study. (ii) Diagnosed spinal stenosis
(iii) Patients must have a baseline score ≥40mm on the
VAS pain scale.
(iii) Back pain potentially attributable to speciﬁc underlying diseases or
conditions (e.g., pregnancy, metastatic cancer, spondylolisthesis,
fractured bones, dislocated joints, disc eruption).
(iv) If taking analgesics,patients must agree to maintain a
steady regimen for the duration of the study. (iv) Unstable medical or severe psychiatric conditions or dementia
(v) Able to provide written and verbal informed consent. (v) Previous back surgery
(vi) Physically unable to undergo treatment
(vii) Patients receiving worker’s compensation or those involved in
litigation
(viii) History of pacemaker, implantable devices, or of cardiac
arrhythmias
(ix) Allergy or intolerance to adhesive materials
(x) Clinical evidence of cardiovascular, pulmonary, renal, hepatic,
neurological, hematological,or endocrine abnormalities.
(European guidelines for the management of chronic nonspeciﬁc low back pain, European Commission COST B13 Management Committee; 2004).
waveelectrical pulses’ frequencyrange is 1–8Hz,pulse width
is 50–800μSw i t hac u r r e n to f0 . 1 – 4 0m A .
3.3. Outcome Measures. A series of valid and reliable out-
come measures were used to assess the diﬀerent aspects of
factors related to LBP.
The visual analog scale (VAS) was chosen as the primary
outcome measure and used to quantify pain intensity. The
VAS, shown to be a reliable and valid measure, consists
of a standard 100mm line with verbal anchors indicating
“none” at one end (0) and “worst imaginable pain” at the
other (100). Participants were told to estimate their current
level of pain by indicating an appropriate mark on the
line. A 20mm reduction in pain intensity, measured on
the VAS scale, resulting from the treatment, was deﬁned as
minimal clinically signiﬁcant intensity diﬀerences (MCID)
[12–14]. Secondary outcome measures were the Oswestry
Disability Index (ODI) and lumbar ﬂexion range of motion
(ROM). The Oswestry Disability Index is a self-completed
questionnaire by the patient which examines perceived levels
of disability in 10 everyday activities of daily living to assign
a subjective score of level of function. Minimal detectable
change (90% conﬁdence) is 10% while a smaller change may
be attributable to error in the measurement [15, 16].
Flexion Hip-Lumbar Spine Range of Motion (ROM):
ﬁnger-to-ﬂoor method involved the subject standing with
feet on either side while a measurement of distance in
centimeters above and below the knee obtained after each
week of treatment was compared to baseline values. Patients
that demonstrated a full range of motion at baseline (ﬁnger
reaching the ﬂoor) were not included in the analysis.
3.4. Statistical Analysis. Categorical data are presented as
absolute and relative frequencies.
Continuous data are presented as means ± SD, median,
and range. Comparisons between various stages in the treat-
ment series were analyzed with paired sample t-tests.
Whenever a statistically signiﬁcant diﬀerence was found, a
95% conﬁdence interval of the diﬀerence was calculated.
Diﬀerences between the weeks were analyzed with the
Wilcoxon Signed Ranks Test. The critical level of signiﬁcance
was 0.05 and the P values presented are always 2 sided. The
statistical software used was SPSS 17.0.
4.Results
Twenty-two patients who fulﬁlled the inclusion criteria were
enrolled. Three of these patients were removed from the
study prior to treatment initiation because they scored
<40mm on the VAS immediately before the ﬁrst treatment.
Thesedropoutswereexcludedfromallanalyses.Hence,nine-
teen patients (5 men and 14 women) were included in the
study. Their mean age was 52.1 ± 10.8 years (median = 56;
range 27–71). The mean ± SD baseline VAS score for all par-
ticipants was 61 ± 14. There were no signiﬁcant changes in
VAS scores between enrollment and the ﬁrst treatment (55.5
± 16.4; P = .10). During treatment, VAS scores decreased
signiﬁcantly compared to baseline by 39 ± 17 (P< . 001).
Notably, VAS scores of all the patients, except one, decreased
by more than 20mm after the fourth treatment, thus
showing a marked improvement in 95% of enrolled patients.
Figure 2shows thediﬀerencebetweenbaselineandposttreat-
ment VAS scores. The mean ±SDbaseline ODIforall partic-
ipants was 26 ± 14 (range 8–64). ODI decreased throughout
the entire treatment period. A signiﬁcant change from base-
line was notable in the third week of treatment (Figure 3),
with a mean improvement of 14.3 ± 10 (P<. 001). Lumbar
ﬂexion ROM showed a mean increase of 2.1cm during
treatment, but this change was not statistically signiﬁcant.
4.1. Adverse Eﬀects. No serious adverse eﬀects were reported
by any of the participants. One patient reported a mild4 Pain Research and Treatment
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Figure 2: Diﬀerence between baseline and posttreatment VAS
scores: VAS scores of all the patients, except one, decreased by more
than 20mm after the fourth treatment, thus showing a marked
improvement in 95% of enrolled patients.
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Figure 3: The mean ± SD baseline ODI for all participants was 26
± 14 (range 8–64). ODI decreased throughout the entire treatment
period. A signiﬁcant change from baseline was notable in the third
week of treatment, with a mean improvement of 14.3 ± 10 (P<
.001).
tingling in the back, which resolved itself within 6 hours of
onset.
5.Discussion
The current pilot study was aimed to assess the eﬀectiveness
of a new, innovative neurostimulation modality in the
treatment of LBP.
Localized decrease in skin resistance is frequently associ-
ated with clinically active myofascial trigger points that are
richly innervated by myelinated A δ ﬁbers, the smallest in
diameter (0.2–1.5μm) and most commonly present mye-
linated axons in peripheral nerves. Their extremely small
size prevents their identiﬁcation by any imaging modal-
ity. However, impedance mapping combined with smart
algorithms allowed their identiﬁcation due to their low
impedance relative to the surrounding area [17]. Electrical
skin impedance measurements are considered to be vulner-
able to certain sources of imprecision, including instrument
error resulting from the size, pressure, and durationof probe
application as well as local skin conditions such as variable
thickness, hydration, and intactness of the stratum corneum
[17, 18]. To overcome these limitations, a new modality was
developed (Nervo-Stim), using an array of miniature probes
combined with an automatic screening capability based on
impedance measurements over the back with simultaneous
multipoint electric high-intensity neurostimulation.
T h em e c h a n i s mo ft h ea n a l g e s i ce ﬀect of the new
modality is not clear. Nevertheless, considerable evidence
suggests that with the type of neurostimulation utilized
analgesia is achieved by activating extra segmental antinoci-
ceptive mechanisms and release of endogenous endorphins,
serotonin, and cortisol [10, 11, 19, 20]. The pituitary has
been implicated in analgesia mediated through the release
of endorphins. The endorphin moiety travels either via the
blood stream to inhibit cells in the substancia gelatinosa
of the spinal cord or via a reverse portal system into the
cerebrospinalﬂuidofthirdventricletoproduceeﬀectsonthe
periaqueductal grey matter [21].
Other nonpharmacological therapies for LBP, such as
TENS units, have been used for 3 decades. These are applied
on large surface areas delivering low-intensity electrical
stimulation to the underlying muscle nerves (type I ﬁbers)
designed to block the pain signal (gate mechanism) to
the brain with a reported eﬀectiveness of 45% rather than
36% in placebo treatments [9]. The American Academy
of Neurology has advised against the use of TENS for the
treatment of chronic LBP, stating that the strongest evidence
i n d i c a t e st h a ti ti si n e ﬀective for this condition [22].
Percutaneous electrical nerve stimulation combines the
advantages of transcutaneous electrical nerve stimulation
(i.e., peripheral dermatomal-based electrical nerve stimula-
tion) and electroacupuncture (i.e., electrical stimulation at
speciﬁc acupoints via percutaneously placed needles). The
main advantage of PENS over TENS is that it bypasses
local skin resistance and delivers electrical stimuli in close
proximity to the nerve endings located in soft tissue, muscle,
or periosteum with 91% of the patients reporting that
PENS was more eﬀective than TENS in decreasing their LBP
[6, 7].
The novel modality described herein was highly eﬀective
in producing acute analgesia in this LBP population with
95%ofpatientsreporting asigniﬁcant decreaseinVASscores
after four treatment sessions. More importantly, the patients
began to report more sustained beneﬁcial eﬀects on their
level of pain and physical activity after 3 to 4 Nervo-Stim
treatments (Figures 2 and 3). This may suggest that Nervo-
Stimproducesacumulativeanalgesiceﬀectoverthecourseof
a 3-week treatment period. The main advantages of the new
device are the capacity to automatically identify LBP trigger
point and to stimulate them without using needles and with
nopreviousknowledgeoftheirlocation.Thus,screeningand
stimulation are performed in a single 25-minute session in a
“user-friendly fashion.”Pain Research and Treatment 5
The major limitations of the study design are the small
sample size, the absence of a control group, and that
control group without treatment may improve low back
pain as time passes. For these reasons, this study should be
regarded as a pilot study only. A larger, randomized, con-
trolled trial is needed for conﬁrmation of these preliminary
results.
6.Conclusion
The results of the current pilot study are encouraging. The
mean VAS scores of participants who received Nervo-Stim
treatment showed a clinically signiﬁcant reduction in back
pain in 95% of patients after four treatment sessions. The
decrease in pain and perceived disability, combined with
the improvement in ROM, support future investigations to
determine the relative eﬀectiveness of varying frequencies
and durations of electrical stimulation using this novel
modality and RCT longitudinal studies in the treatment of
LBP.
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